JP Morgan Chase
CRVS icon

JP Morgan Chase’s Corvus Pharmaceuticals CRVS Stock Holding History

JP Morgan Chase’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100
Closed -$176 – 7482
2023
Q4 		$176 Buy
+100
New +$146 ﹤0.01% 7064

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

JP Morgan Chase's CRVS Position: Q2 2026 in Review

JP Morgan Chase reduced its Corvus Pharmaceuticals (CRVS) stake by 2.2% in Q2 2026, selling an estimated $44K and leaving 141,986 shares worth $2.06M. The position accounts for ﹤0.01% of the portfolio, ranked #4157.

JP Morgan Chase first reported a position in CRVS in Q2 2016 and has held it in 32 quarters since. The position peaked at $5.11M in Q3 2017. 174 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • JP Morgan Chase held 141,986 shares of Corvus Pharmaceuticals worth $2.06M as of Q2 2026.
  • JP Morgan Chase sold 3,171 Corvus Pharmaceuticals shares in Q2 2026, an estimated $44K.
  • Corvus Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4157 holding.
  • JP Morgan Chase first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 32 quarters since.
  • JP Morgan Chase's Corvus Pharmaceuticals position peaked at $5.11M in Q3 2017.
  • 174 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.